Amphastar PharmaceuticalsAMPH
AMPH
About: Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Employees: 2,028
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
220% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $318K
0.93% more ownership
Funds ownership: 72.77% [Q3] → 73.69% (+0.93%) [Q4]
5% less funds holding
Funds holding: 276 [Q3] → 263 (-13) [Q4]
16% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 100
23% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 48
23% less capital invested
Capital invested by funds: $1.72B [Q3] → $1.32B (-$396M) [Q4]
67% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 1 (-2) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$36
38%
upside
Avg. target
$36
38%
upside
High target
$36
38%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Piper Sandler David Amsellem 51% 1-year accuracy 18 / 35 met price target | 38%upside $36 | Neutral Downgraded | 4 Feb 2025 |
Financial journalist opinion
Based on 22 articles about AMPH published over the past 30 days
Neutral
Accesswire
1 week ago
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations will be presenting at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, 2025, at 10:30 am ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Neutral
Accesswire
1 week ago
Amphastar Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AMPH
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Neutral
Accesswire
1 week ago
AMPH ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Amphastar Pharmaceuticals, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Negative
Benzinga
1 week ago
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
On Thursday, Amphastar Pharmaceuticals Inc. AMPH reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents.
Negative
The Motley Fool
1 week ago
Amphastar: Earnings Miss, Margins Drop
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.
Neutral
Accesswire
1 week ago
Amphastar Pharmaceuticals, Inc. Being Investigated on Behalf of Amphastar Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.
Neutral
Seeking Alpha
1 week ago
Amphastar Pharmaceuticals Inc. (AMPH) Q4 2024 Earnings Call Transcript
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Jason Gerberry - Bank of America Cerena Chen - Wells Fargo Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Serge Belanger - Needham & Company Operator Greetings and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode.
Positive
Zacks Investment Research
1 week ago
Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
1 week ago
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.92 per share, missing the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.88 per share a year ago.
Neutral
Accesswire
1 week ago
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024
Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA / ACCESS Newswire / February 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full year ended December 31, 2024. Fourth quarter Highlights Net revenues of $186.5 million for the fourth quarter GAAP net income of $38.0 million, or $0.74 per share, for the fourth quarter Adjusted non-GAAP net income of $47.2 million, or $0.92 per share, for the fourth quarter Full Year Highlights Net revenues of $732.0 million for the fiscal year GAAP net income of $159.5 million, or $3.06 per share, for the fiscal year Adjusted non-GAAP net income of $200.8 million, or $3.86 per share, for the fiscal year Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are incredibly proud that in 2024, we exceeded our long-term goal of achieving $100 million in annual sales for Primatene MIST®, and we look forward to continuing to grow the brand.
Charts implemented using Lightweight Charts™